Harmony Biosciences Holdings, Inc. announced that new safety and efficacy data from a Phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in patients with Prader-Willi syndrome (PWS) will be highlighted as a poster presentation during a late-breaking abstract session at the 37th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2023," in Indianapolis from June 3-7. Additional presentations by Harmony include an oral presentation covering a pooled analysis of clinically meaningful improvements in adults with narcolepsy, as well as poster presentations detailing the results of a pharmacokinetics study of WAKIX in breast milk and serum in healthy lactating women, and an ongoing prospective observational safety study evaluating WAKIX exposure in pregnant women and their offspring.